Latest Insider Transactions at Eye Point Pharmaceuticals, Inc. (EYPT)
This section provides a real-time view of insider transactions for Eye Point Pharmaceuticals, Inc. (EYPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EyePoint Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EyePoint Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2021
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,702
-18.74%
|
$17,020
$10.81 P/Share
|
|
Feb 28
2021
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+31.13%
|
-
|
|
Feb 28
2021
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,423
-10.93%
|
$14,230
$10.81 P/Share
|
|
Feb 28
2021
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,105
+23.98%
|
-
|
|
Feb 21
2021
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
13,717
+12.44%
|
-
|